Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

"Köpfe" der aktuellen Meldungen:

Nina Höller

Nariae Baik-Schneditz

Bernhard Schwaberger

Lukas Peter Mileder

Niels Hammer

Gerhard Pichler

Roland Malli

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Scharnagl, H; Vogel, M; Abletshauser, C; Freisinger, F; Stojakovic, T; März, W.
Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administration.
Cardiology. 2006; 106(4): 241-248. Doi: 10.1159/000093200
Web of Science PubMed FullText FullText_MUG Google Scholar

Führende Autor*innen der Med Uni Graz: Scharnagl Hubert
Co-Autor*innen der Med Uni Graz: März Winfried; Stojakovic Tatjana
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Flexibility in the time of administration of statin therapy is likely to improve patient compliance. This study compared the efficacy and tolerability of morning and evening administration of the extended-release formulation of fluvastatin (fluvastatin XL). METHODS: In this prospective, double-blind, multicenter, multiple dose study, 236 patients with type IIa/b hypercholesterolemia were randomized to receive fluvastatin XL, 80 mg, in the morning or evening for 8 weeks. RESULTS: At 8 weeks, low-density lipoprotein cholesterol levels were reduced by 34.5 and 35.0% in the morning and evening treatment groups, respectively (p = 0.0118 for non-inferiority of morning administration). There were no statistically significant differences between the morning and evening treatment groups in the changes in total cholesterol (p = 0.56), high-density lipoprotein cholesterol (p = 0.21), triglycerides (p = 0.13), apolipoprotein B (p = 0.66) and apolipoprotein AI (p = 0.88) at 8 weeks. The frequency of adverse events was slightly lower in the morning treatment group compared with the evening treatment group (27.4 vs. 35.5%). CONCLUSIONS: The efficacy and safety profiles of fluvastatin XL are equivalent for morning and evening administration.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Aged, 80 and over -; Anticholesteremic Agents - administration and dosage; Apolipoproteins B - blood; C-Reactive Protein - metabolism; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Circadian Rhythm - blood; Delayed-Action Preparations - blood; Fatty Acids, Monounsaturated - administration and dosage; Female - administration and dosage; Homocysteine - blood; Humans - blood; Hypercholesterolemia - blood; Indoles - administration and dosage; Male - administration and dosage; Middle Aged - administration and dosage; Prospective Studies - administration and dosage; Treatment Outcome - administration and dosage
Find related publications in this database (Keywords): fluvastatin; morning; evening; administration